ory-2001
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started May 16, 2019 (NCT03867253)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- LSD1/CoREST complexINHIBITOR
LSD1/CoREST complex inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Nc1nnc(CN[C@@H]2C[C@H]2c2ccc(OCc3ccccc3)cc2)o1- Mol. weight
- 336.4 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4802155 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04932291 | Phase 2 | Mar 26, 2021 | Oryzon Genomics S.A. |
| NCT03867253 | Phase 2 | May 16, 2019 | Alzheimer’s Drug Discovery Foundation, Oryzon Genomics S.A. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Oryzon Genomics S.A. | For profit | 2 | 2 | 1 | 2019 |
| Alzheimer’s Drug Discovery Foundation | Academic/Hospital | 1 | 0 | 1 | 2019 |
2 organizations
Page 1 / 1